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Abstract The aim of this study was to estimate the
cost-eVectiveness of 18FDG-PET in the selection for direct
laryngoscopy in patients with suspicion of recurrent laryn-
geal carcinoma after radiotherapy. The direct medical costs
of 30 patients with suspicion of a recurrence were calcu-
lated from the Wrst visit where suspicion was raised until
one year after. A conventional strategy, in which all these
patients underwent direct laryngoscopy, was compared to
an 18FDG-PET strategy in which only patients with a posi-
tive or equivocal 18FDG-PET underwent direct laryngos-
copy. A sensitivity analysis was performed to examine the
inXuence of the type of camera and ‘setting’. The mean
costs of an 18FDG-PET strategy were D399 less than a
direct laryngoscopy strategy. The type of camera and set-
ting had no inXuence. In patients with suspicion for recur-
rent laryngeal carcinoma after radiotherapy, 18FDG-PET
seems to be eVective and less costly in selecting patients for
direct laryngoscopy.
Keywords Cost-eVectiveness · Recurrent laryngeal 
carcinoma · Radiotherapy · 18FDG-PET
Introduction
Laryngeal cancer is the most common cancer of the head
and neck. Each year around 700 new cases of laryngeal car-
cinoma are diagnosed in The Netherlands [1]. Early laryn-
geal cancer can usually be managed successfully with
either radiotherapy or surgery. Advanced stage disease is
often treated with a combination of treatment modalities.
Many laryngeal carcinomas are treated with radiotherapy
with or without chemotherapy with surgery for salvage in
case of recurrence. Depending on tumour stage, the local
recurrence rate varies from 10 to 50% [2]. Distinguishing
between recurrent carcinoma and radiotherapeutic sequels
frequently poses a diYcult clinical problem. Computed
tomography (CT) and magnetic resonance imaging (MRI)
are the most commonly used diagnostic methods in primary
laryngeal carcinoma. When recurrent laryngeal cancer is
suspected they seem to be less eVective, unless a base-line
posttreatment scan is performed [3–7]. Therefore, patients
with clinical suspicion of recurrent laryngeal cancer almost
invariably undergo a direct laryngoscopy under general
anaesthesia with taking of biopsies. It has been shown that
less than 50% of these procedures show recurrence. There-
fore, more than 50% of these direct laryngoscopies are
futile with unnecessary general anaesthesia and risk of
exacerbation of postradiotherapy changes [6]. F18-deoxy-
glucose (18FDG) Positron Emission Tomography (PET)
could be able to distinguish between recurrent tumour and
radiation sequelae and the Wrst results of 18FDG-PET in the
diagnosis of recurrent laryngeal cancer are promising. In
previous studies a speciWcity of 80–100%, a positive pre-
dictive value of 67–89% and negative predictive value of
80–100% has been reported [8–12].
Current health policy makers rightfully dictate the need
for economic evaluations of new expensive diagnostic
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techniques, such as 18FDG-PET [13]. Next to accuracy
data, the cost eVectiveness of 18FDG-PET in the diagnosis
of recurrent laryngeal cancer thus needs to be investigated.
In fact two diagnostic strategies have to be compared: In
the conventional strategy all patients undergo direct laryn-
goscopy under general anaesthesia with taking of biopsies
if necessary. In the 18FDG-PET strategy only patients with
a positive or equivocal 18FDG-PET undergo direct laryn-
goscopy. In the latter strategy 18FDG-PET was used as
selection method for performing direct laryngoscopy. The
aim of the present study was to compare the costs of both
strategies.
Patients and methods
Patients and clinical procedures
In this retrospective study, data of 30 patients who were
seen between 1998 and 2001 with suspicion of recurrent
laryngeal cancer after radiotherapy were analysed. All
patients had radiotherapy for a primary laryngeal carcinoma.
The distribution of tumour subsites was 63% glottis, 33%
supraglottis and 3% subglottis. Ten percent of the patients
were staged T1, 43% T2, 20% T3 and 27% T4 (Table 1).
All patients underwent a direct laryngoscopy with
biopsies under general anaesthesia as well as a single
18FDG-PET scan. The median interval between the last
radiation fraction and the PET scan was 8.7 months (range
2.4–32.1 months). They were all studied after fasting over-
night. Preceding the 18FDG-PET studies, the patients’
plasma glucose level was measured. Sixty minutes after
intravenous administration of 370 MBq, 18FDG imaging of
the head and neck region was performed by scanning two
bed positions. The 18FDG-PET scans were done by two
technologists and a nuclear physician and performed before
the laryngoscopy to avoid false-positive 18FDG-PET Wnd-
ings as a result of trauma due to the biopsies taken.
In both (modelled) strategies patients had regular follow-
up visits after 18FDG-PET and direct laryngoscopy. Histo-
pathological examination of the biopsy taken or primary
tumour status after 12 months of follow-up was used as the
reference standard. With the results of both diagnostic tests
a decision tree with Wve paths was constructed (Fig. 1). Sal-
vage laryngectomy was advised in case of recurrence.
Cost eVectiveness
The costs of medical consumption in all paths (conven-
tional and 18FDG-PET based) of the decision tree were ana-
lysed, as well as the eVects.
Costs
The study was performed from an institutional perspective.
The follow-up period was 12 months after the outpatient
visit, where suspicion of recurrence was raised. This study
period was divided in three phases: diagnostic, treatment
and follow-up phase. The cost analysis was based on the
direct medical costs. Medical tests not related to the laryn-
geal cancer were not taken into account. The cost categories
considered were amongst others, operations, in-hospital
days, 18FDG-PET scans, visits, imaging techniques, labora-
tory examinations, pulmonary function, physical therapy,
blood products, speech therapy and pathology. For the most
important items in the medical consumption, unit costs by
using the microcosting method were calculated. This
method is based on an inventory of consumed materials,
hospital personal and overhead costs [14, 15]. Unit prices
calculated in previous studies and tariVs were used for less
expensive tests [16–19]. The mean costs per patient were
categorised in operations, in-hospital days, visits and oth-
ers. The costs were expressed in euros in the year 2003.
Unit cost of 18FDG-PET
The unit cost of the 18FDG-PET scan consisted of costs
made for equipment, personal, material and overhead costs.
Table 1 Number of patients in 
the several tumour and lymph 
node (N) stages of the primary 
laryngeal carcinoma
N0 N1 N2
T1 3 0 0
T2 10 2 1
T3 5 1 0
T4 6 1 1
Fig. 1 Study model
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Depreciation over 7 years was used to calculate yearly
investment costs for the PET scanner. Yearly maintenance
costs were 8% of the price paid for the PET scanner and
computer equipment. These costs were accounted according
to the 18FDG-PET utilisation time for a head and neck
18FDG-PET scan and the time the PET scanner was used
per year. The costs of 18FDG were based on the price paid
per month for a Wxed number of patient injections. The cost
of staV was valued by internal unit costs of the hospital
accounting system. To account for the overhead costs for
infrastructure service, a standard mark up percentage of
35% on all operating costs was used.
For the calculation of a unit cost of 18FDG-PET it is
important to distinguish between a covered and a non-
covered setting, i.e. in a situation of using 18FDG-PET for
research purposes. When not all 18FDG-PET scans are
covered, then these scans should be ascribed to the unit
costs of the 18FDG-PET scan which are covered. In this
study this is called the non-covered academic setting. The
unit cost price of the 18FDG-PET and the 18FDG-PET-CT
in an academic setting and in a non-covered academic set-
ting were calculated for the standard procedure of 15 min.
The cost of the mobile PET scanner was based on the rent
paid for the mobile PET scanner and the hospital personal
needed. The cost of 18FDG was based on the mean price
of 370 MBq charged by Tyco Healthcare (Zaltbommel,
The Netherlands). The total costs of both strategies were
calculated for the various 18FDG-PET and 18FDG-PET-
CT settings.
EVectiveness
The eVects were expressed as the number of direct
laryngoscopies avoided, mean cost per strategy within
12 months and costs saved per avoided direct laryngo-
scopy.
Sensitivity analysis
The cost of 18FDG-PET could be inXuenced by the type of
camera (PET, PET-CT, mobile PET) and ‘setting’ (aca-
demic, non-covered academic hospital). Because there
were no studies, which compare 18FDG-PET and 18FDG-
PET-CT for this speciWc indication, it is assumed in this
analysis that both imaging techniques detect residual laryn-
geal carcinoma after radiotherapy equally well. The
eYciency of 18FDG-PET in the diagnosis of recurrent
laryngeal cancer could also depend on the sensitivity and
speciWcity of 18FDG-PET, examination time of 18FDG-PET
as well as the prevalence of recurrences in the studied
population. The inXuence of these parameters on the
eYciency of 18FDG-PET was therefore analysed in the
sensitivity analysis.
Statistical analysis
In this study the mean costs per patient per cost category
are reported. The 95% variance was calculated for each
category in each phase. Statistical signiWcance between the
various strategies was not calculated due to the small
number of patients.
Results
Clinical results
The direct costs of 30 patients, 22 men and 8 women (mean
age 64.0; range 52–82) were examined. The prevalence of
recurrent laryngeal cancer in this study was 0.233.
For direct laryngoscopy the sensitivity, speciWcity, posi-
tive as well as the negative predictive value in this study
were 1.0 since no additional recurrences were detected
during 12 months of follow-up. The positive test probability
was 0.233. The negative test probability was 0.767. For
18FDG-PET the sensitivity was 1.0, the speciWcity was
0.86. The positive and negative predictive values were,
respectively, 0.64 and 1.0. The positive test probability was
0.367. The sensitivity of 1.0 in this study implied that no
patient was denied a direct laryngoscopy if selection
was based on 18FDG-PET. In total 19 direct laryngos-
copies would have been avoided if 18FDG-PET was used
for selection.
There were four false-positive 18FDG-PET scans in the
18FDG-PET strategy for which no obvious explanation
other than post-radiotherapy inXammatory changes was
found. Four patients with recurrent laryngeal cancer had a
total laryngectomy. None of these patients with recurrent
tumour were suitable for partial laryngectomy. One patient
refused, another patient died within 1 month and in one
patient the tumour was inoperable. Two patients underwent
microlaryngoscopy and CO2-laser treatment of oedema
because of dyspnoea complaints. The costs of these opera-
tions were also taken into account.
Cost analysis
The unit cost price of 18FDG-PET amounted to D 521 (Per-
sonal (P) D29; Material (M) D356; Overhead (O) D135).
The cost price of 18FDG-PET in a non-covered academic
setting, amounted to D 1156 (P D333; M D 523; O D300).
The cost price of a mobile 18FDG-PET was D 611 (P D 29;
M D 423; O D 158).
The mean costs were assigned to four categories; opera-
tions, in-hospital days, visits and others (Table 2). The
mean costs per patient for the conventional strategy were,
respectively, D2.205, D1.480 and D9.545 for the diagnostic,1444 Eur Arch Otorhinolaryngol (2009) 266:1441–1448
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treatment and follow-up phase, resulting in overall mean
costs of D13.230. For the 18FDG-PET-based strategy the
mean costs per patient for the diVerent phases were, respec-
tively, D1.806, D 1.480 and D9.545. The overall mean costs
per patients for the 18FDG-PET-based strategy were
D12.832 (Table 3). Therefore, a diagnostic strategy in
which 18FDG-PET would have been used to select patients
for direct laryngoscopy costs D399 less per patient than the
conventional strategy in which all patients with suspicion
of recurrent laryngeal carcinoma after radiotherapy had a
direct laryngoscopy. Because in the 18FDG-PET-based
strategy 19 of the 30 patients would not undergo a direct
laryngoscopy, 18FDG-PET saves D630 per avoided laryn-
goscopy. The costs of the follow-up phase consisted mainly
of costs of surgical treatment in case of recurrence.
Sensitivity analysis
In an academic setting the strategy based on FDG-PET,
18FDG-PET-CT and mobile 18FDG-PET cost between
D309 and D399 less per patient compared to the conven-
tional strategy (Table 4). In a non-covered academic setting
the strategy based on 18FDG-PET and 18FDG-PET-CT cost,
respectively, D236 and D344 more than the conventional
strategy. An increase of the prevalence and a decrease of
the speciWcity resulted in an increase of the mean cost of
the 18FDG-PET scenario. SpeciWcity above 0.5 and preva-
lence less than 0.5 resulted in lower mean costs per patient
for the 18FDG-PET scenario (Table 5).
Discussion
In this retrospective study the cost-eVectiveness of an
18FDG-PET-based strategy in comparison with a conven-
tional strategy in patients with suspicion of recurrent laryn-
geal carcinoma after radiotherapy was determined. 18FDG-
PET had a sensitivity and speciWcity of 1.0 and 0.86,
respectively. The costs of the 18FDG-PET-strategy were
D399 lower per patient than the conventional method using
a direct laryngoscopy for all patients. Therefore, it can be
concluded that 18FDG-PET is eVective and not costlier in
selecting patients with suspicion of recurrent laryngeal car-
cinoma after radiotherapy for direct laryngoscopy under
general anaesthesia. This was the case for all settings of
18FDG-PET and 18FDG-PET-CT, except from cases when
the costs of research are not fully covered.
The need for economic evaluations of new technologies
like PET has been recognised. Nevertheless, economic
evaluations have remained under-utilised in nuclear medi-
cine. Furthermore economic evaluation studies in nuclear
medicine diVered widely in terms of form of evaluation,
outcome measures and costing [20]. Only one study calcu-
lated the costs of 18FDG-PET in the diagnosis of recurrent
laryngeal cancer. In a limited cost-eVectiveness study, Bon-
gers et al. [21] found that implementation of 18FDG-PET
using a dual-head camera in the detection of recurrent
laryngeal cancer has additional costs of 64 Euro per patient.
In the present study a more extensive cost-analysis is
performed using a dedicated full-ring PET-scanner. The
Table 3 Mean and median costs in euros per phase per path
Path Description  Diagnostic phase Treatment phase Follow-up phase Total
Mean Median Mean Median Mean Median Mean Median
1 Laryngoscopy + follow-up D2.054  D1.918  D403  D0  D9.254  D1.729  D11.712  D3.595 
2 Laryngoscopy + laryngectomy D2.701  D2.303  D5.016  D4.548  D10.500  D8.822  D18.217  D16.246 
Mean costs laryngoscopy per patient D2.205  D1.480  D9.545  D13.230 
3 PET + follow-up D1.046  D935  D488  D0  D9.247  D1.639  D10.781  D2.418 
4 PET + laryngoscopy + follow-up D2.937  D2.603  D0  D0  D9.292  D7.764  D12.229  D10.367 
5 PET + laryngoscopy + laryngectomy D3.222  D2.928  D5.016  D4.603  D10.500  D9.517  D18.738  D18.554 
Mean cost PET per patient D1.806  D1.480  D9.545  D12.831 
Table 4 Mean costs per patient 
per setting (costs in euros)
PET (CT) Direct 
laryngoscopy
PET(CT) vs. 
laryngoscopy
PET academic setting D12.831 D13.230 ¡D399
PET non-covered academic setting D13.466 D13.230 D236
Moblie PET D12.921 D13.230 ¡D309
PET/CT academic setting D12.905 D13.230 ¡D325
PET/CT non-covered academic setting D13.574 D13.230 D344
vs versus1446 Eur Arch Otorhinolaryngol (2009) 266:1441–1448
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quality of life of patients was not taken into account,
although there were probably more negative side eVects in
the conventional strategy. As in all diagnostic imaging
techniques, there is an interobserver variability in reporting
the scans. This may inXuence the overall cost-eVectiveness
of 18FDG-PET. A calculation of this was not performed in
this study.
The 18FDG-PET-based strategy in this study showed no
false-negative test results. Therefore, no patients would
have been wrongly denied further diagnostics and eventual
therapy. Although the patientgroup was originally included
consecutively, some patients were lost in retrospect because
not enough data were available to calculate the costs. This
led to a group with a coincidental high sensitivity of
18FDG-PET of 100%. In a systematic review by Brouwer
et al. [22] the pooled sensitivity was 89% and this is a more
valid number than 100%. False negative results in a 18FDG-
PET strategy will carry the risk of missing recurrent disease
at the earliest possible stage. Such delay may potentially
adversely aVect prognosis and reduce the possibility for
laryngeal preservation treatment. It may also induce extra
costs.
The results of this study though, are in agreement
with the results of a study by Terhaard et al. [12]. They
concluded that a18FDG-PET scan should be the Wrst
diagnostic step when a local recurrence is suspected
after radiotherapy and in case of a negative 18FDG-PET
scan no direct laryngoscopy with taking of biopsies is
needed.
In this study the prevalence was only 23%. However, in
a study by Brouwer et al. [3] the prevalence was 45%.
DiVerences in prevalence between studies are commonly
found. In the present study half of the patients had
advanced primary tumours. The probability of recurrence in
advanced primary tumours is considered higher. There is a
tendency to treat advanced laryngeal cancer with concomi-
tant radiotherapy and chemotherapy. If the percentage of
patients treated for advanced primary tumours would have
been higher, the prevalence of recurrent disease would be
higher and consequently the 18FDG-PET-based strategy
would have been less cost eVective. On the other hand, in a
previous study, it was shown that patients with advanced stage
laryngeal carcinoma needed most direct laryngoscopies
[3]. From that point of view it can be anticipated that patients
with advanced primary tumours may particularly beneWt
from an 18FDG-PET based strategy.
Another reason for the diVerent prevalence may be the
inclusion criteria. In the retrospective study of Brouwer
et al. [3] all patients who underwent direct laryngoscopies
were included. Because of the retrospective nature of this
study it was not possible to analyse the degree of suspicion.
Probably also patients were included in whom recurrence
was obvious and direct laryngoscopy was only performed
for histopathological proof and treatment planning. In these
patients PET has no additional value. In the present study
only patients with some degree of suspicion were included,
and no clear recurrences. In our ongoing prospective ran-
domized multicenter study, the degree of suspicion is
Table 5 InXuence of prevalence on the mean costs in euros per patient
T+ costs of patients with recurrent tumour, T¡ costs of patients without recurrent tumour
Mean costs per patient PET sensitivity = 1 and varying prevalence and speciWcity
Prevalence speciWcity 0.1 0.2 0.233 0 . 30 . 40 . 50 . 60 . 70 . 80 . 91
0.1 12.750 13.415 13.637 14.080 14.746 15.411 16.076 16.742 17.407 18.073 18.738 
0.2 12.619 13.299 13.526 13.979 14.659 15.339 16.019 16.698 17.378 18.058 18.738 
0.3 12.489 13.183 13.415 13.878 14.572 15.266 15.961 16.655 17.349 18.044 18.738 
0.4 12.359 13.067 13.304 13.776 14.485 15.194 15.903 16.612 17.320 18.029 18.738 
0.5 12.228 12.952 13.193 13.675 14.398 15.122 15.845 16.568 17.291 18.015 18.738 
0.6 12.098 12.836 13.082 13.574 14.311 15.049 15.787 16.525 17.262 18.000 18.738 
0.7 11.968 12.720 12.971 13.472 14.224 14.977 15.729 16.481 17.233 17.986 18.738 
0.8 11.837 12.604 12.860 13.371 14.138 14.904 15.671 16.438 17.205 17.971 18.738 
0.83 11.803 12.574 12.831 13.344 14.115 14.885 15.656 16.426 17.197 17.967 18.738
0.9 11.707 12.488 12.749 13.269 14.051 14.832 15.613 16.394 17.176 17.957 18.738 
1 11.577 12.372 12.638 13.168 13.964 14.760 15.555 16.351 17.147 17.942 18.738
Mean costs per patient direct laryngoscopy Sensitivity and SpeciWcity 1,0 and varying prevalence
0.1 0.2 0.233 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
T+ 1.822  3.643  4.251  5.465  7.287  9.108  10.930 12.752 14.574 16.395 18.217 
T¡ 10.540  9.369 8.979  8.198 7.027  5.856  4.685 3.513 2.342 1.171 0 
Total 12.362 13.013 13.230 13.663 14.314 14.964 15.615 16.265 16.916 17.566 18.217 Eur Arch Otorhinolaryngol (2009) 266:1441–1448 1447
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scored when a patient is included [3]. Patient selection on
degree of suspicion will inXuence the prevalence and con-
sequently the cost-eVectiveness. If patients with clear recur-
rences are included the costs of a 18FDG-PET based
strategy will be higher.
Since both the conventional and the 18FDG-PET-based
strategy showed no false-negative test results in this study,
these pathways are absent in the decision model used. An esti-
mation of the costs and the eVects of false-negative Wndings
can not be made. Second, because of the absence of false-
negative 18FDG-PET scans, the inXuence of sensitivity of
18FDG-PET can therefore not be tested in a sensitivity analysis.
As previously stated, cost-eVectiveness studies diVer in
terms of evaluation and costing. The costs of an 18FDG-
PET scan depends, e.g. on the number of 18FDG-PET
studies per PET camera, type of PET camera, number of bed
positions, time per bed position, costs of 18FDG, number of
technologists and nuclear physicians. For an 18FDG-PET
scan of the head and neck two bed positions were scanned
with a total time of 15 min per patient. 18FDG-PET as
whole-body technique may be performed when screening
for distant metastases is indicated in patient with risk fac-
tors [23]. Because of the diVerent indications a whole-body
18FDG-PET was not used in this study. If a whole-body
scan is used, there is a possible risk that false-positive
lesions are found elsewhere in the body. This would induce
extra costs for further investigation. Since a whole-body
scan was not used in this study, these costs were not calcu-
lated. The extra costs of false-positive results within the
larynx were included.
For the delivery of 18FDG there is only one distributor in
The Netherlands. Probably the price of 18FDG can be
reduced when more distributors enter the market, resulting
in a lower price per 18FDG-PET scan.
Although there are diVerences between health systems
between countries, we think that our Wndings could largely
be generalised to other countries. The results largely
depend on the price of 18FDG-PET scan or 18FDG-PET-CT
scan and the costs of follow-up treatment. In this respect,
we calculated with real cost prices instead of using tariVs.
The used prices are therefore do not depend on a health care
Wnancing system.
Since non-surgical treatments with salvage surgery in
reserve are being popularised, the clinical problem of
detecting recurrent laryngeal carcinoma after radiotherapy
is increasingly important. Therefore, cost-eVectiveness is
also one of the endpoints in an ongoing randomised multi-
centre trial [24].
In conclusion, 18FDG-PET seems to be eVective and not
costlier in selecting patients for direct laryngoscopy under
general anaesthesia to detect recurrent laryngeal carcinoma
after radiotherapy. These Wndings have to be conWrmed in a
prospective randomised clinical trial.
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